Mellon has established a Supervisory Board to provide the necessary guidance to realize its vision: to improve medical procedures by offering the best possible tools.
Jan Hendrik Egberts
Jan Hendrik Egberts, M.D. has over 25 years of experience in the pharmaceutical biotech and, medical devices sector. He gained his medical qualifications from Erasmus University Medical School in the Netherlands and pursued the clinical part of his training at Harvard Medical School. He obtained his MBA from Stanford after which he joined McKinsey & Co. as a strategic consultant in New York. From 1994 onwards he held various business development and general management positions of increasing responsibility in the U.S. at Merck & Co. and Johnson & Johnson. In 2000, he initiated the leveraged buyout of the BARRIER surgical business from Johnson & Johnson and the subsequent merger with Mölnlycke Health Care. After the divestiture of Molnlycke Health Care he became CEO of Novadel Pharmaceuticals, Inc. Subsequently, Dr Egberts served as Senior Advisor, Healthcare Investments for 3i, the private equity firm. Most recently Dr Egberts, served as CEO of OctoPlus a publicly traded specialty pharmaceutical company in the Netherlands which was acquired by Dr Reddy’s from India and subsequently as board member / interim CEO of Agendia, a privately held gene expression company focused on oncology. Dr Egberts currently serves as the Managing Director of Veritas investments, a private investment company focused on equity investments in European and U.S. healthcare companies. During his career, Dr Egberts has held over 30 non-executive supervisory board positions in both public and privately held healthcare companies in the U.S. and various European countries.